As a rule, only those medieval manuscripts that were of interest for the powerful have been preserved. Extant codices were cherished throughout centuries as tangible signs of cultural pre-eminence and carriers of the sacred word; charters were kept as custodians of patrimony and witness to the history of institutions, proclaiming the reasons why monasteries and cathedrals should be revered. But against this rule, other manuscripts that did not directly serve the purposes of high-status minorities were created and are still around. Codices that, belonging to an ecclesiastical rite that was suppressed, should not survive today, but were kept as guardians of tradition. Charters that, intermingled with royal diplomas, have survived without an apparent reason for they do not relate to privileges granted. These sources show us a different side of medieval society in which non-powerful individuals outside central institutions played a crucial role in understanding the implications of written communication, shaping their social memory and that of their past by fully integrating writing in their lives. PeopleAndWriting aims at exploring this common people-writing pairing to uncover what writing meant for lay communities, how it modelled their daily life, and how the use of writing individualised people within their group. From the interdisciplinary study of theses sources that defy the rule, the project proposes a novel method combining approaches from Manuscript Studies to Anthropology to, based upon the graphical, textual, and historical analysis of the sources, reveal the hidden history of the people who wrote, signed, read, and kept handwritten material. Moreover, by focusing on a hitherto unmapped corpus of manuscripts from the Iberian Peninsula, which will be made openly available to the general public, the project aims to integrate Iberia in the recently opened general debate on Medieval Communication, exploring new avenues of research on Written Culture.

Glioblastoma multiforme (GBM) represents the most frequent and aggressive type of primary brain tumours in adults. Despite significant advances, current treatments involving resection and radiation/chemotherapy only partially mitigate the dire prognosis for GBM, hence avidly seeking for novel therapeutic approaches against a disease with still no virtual cure and a high socio-economic impact in the EU. A common feature in GBM, as in many other cancers, is their escape to the retrograde signalling and metabolic regulation exerted by mitochondria -the bioenergetic central of the cell. Modulation of mitochondrial function thus represents a primary target to rewire metabolism and counteract tumour progression and chemotherapy resistance. MITIG capitalizes on the recent reported ability of gliomas to import exogenous mitochondria, either isolated or transferred from surrounding neural cells in the brain, to foster tumour development and malignancy in vivo. MITIG will target both paths for mitochondrial importation to remodel organelle content and address i) how incorporation of exogenous mitochondria impacts respiratory metabolism in GBM cells and iii) the relevance of this metabolic rewiring for tumour development in vivo. Departing from mitochondrial acquisition as a novel tool to redefine respiration and metabolism in cancer, MITIG will develop a comprehensive training program fostering MSCA and EU values on research, dissemination and public engagement. An international network of experts will support the training in the intersectorial, multidisciplinary facets of MITIG. In sum, while paving the way for a promising novel biomedical field, MITIG aims at providing novel therapeutic targets and overcoming long lasting questions on respiratory metabolism in GBM and cancer as a whole.

The emergence of Big Data has revolutionised all fields of knowledge, including health. Indeed, the ever-increased digitisation of the medical records along with the advent of telemedicine (the latter driven by COVID-19 crisis), has increased the availability of patients’ medical data to an extent as never seen before. In addition, the increasing use of “omics” data is providing a huge amount of information that needs to be organised, analysed, and correlated with the clinical, laboratory, imaging, therapy-related, and biological data. Nonetheless, medical information, unlike others, is extremely heterogeneous and non-structured, as well as dynamic and influenced by the disease and therapies. And currently, there is a great “gap” in understanding of its potentials and exploitation by biomedical professionals and its meaning and value by today’s data scientists. Thus, the overall algorithms and tools developed are not optimal for processing medical data, being necessary to understand the entire data cycle to address the analytical and interpretation tasks with guarantees.This project plans to design an innovative master’s degree aiming at training a new generation of professionals able to manage and exploit Big Data in biomedicine, generating meaningful conclusions and, in the long run, impacting decision-making, improving patients’ diagnosis and prognosis and accelerating the development of more effective and precise treatments. To this end, a joint, multidisciplinary, high-quality, and inclusive master’s programme will be designed by a consortium composed of renowned and experienced EU partners.At the end of the project, all the academic, managerial, and financial features of this new master’s degree will be set up, aiming to implement the master’s degree into the EU Higher Education System and to generate, in the long term, a broad workforce able to satisfy a current unmet market need in healthcare.